| Original language | English |
|---|---|
| Pages (from-to) | e73-e74 |
| Journal | CHEST |
| Volume | 147 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2015 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: CHEST, Vol. 147, No. 2, 01.02.2015, p. e73-e74.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Bronchial thermoplasty
T2 - Ready for prime time - The evidence is there!
AU - Castro, Mario
AU - Cox, Gerard
AU - Wechsler, Michael E.
AU - Niven, Robert M.
N1 - Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following conflicts of interest: Dr Castro receives university grant monies from the National Institutes of Health and American Lung Association and pharmaceutical grant monies from Amgen Inc; Boston Scientific Corporation; Ception Therapeutics, Inc and Cephalon Inc, subsidiaries of Teva Pharmaceutical Industries Ltd; Genentech, Inc; GlaxoSmithKline plc; KaloBios; MedImmune, LLC; Nexbio, Inc; Novartis AG; sanofi aventis US LLC; and Vectura Group plc. He receives royalties from Elsevier BV and consultant fees from Boston Scientific Corporation; Genentech, Inc; Holaira Inc; and NeoStem, Inc. Dr Castro receives speaking fees from GlaxoSmithKline plc, Genentech Inc, Boehringer Ingelheim GmbH, Boston Scientific Corporation, and Teva Pharmaceuticals Industries Ltd. He has stock options with Sparo Labs. Dr Cox has participated in clinical research trials of bronchial thermoplasty supported by Asthmatx, Inc/Boston Scientific Corporation and has received consultant and speaking fees related to bronchial thermoplasty. Dr Wechsler has received honoraria from Boston Scientific Corporation for consulting and for speaking engagements. Dr Niven has received lecture fees for international lectures from Boston Scientific Corporation over the past 3 years and has received lecture fees from or participated on the advisory boards of AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis Corporation, and Vectura Group plc.
PY - 2015/2/1
Y1 - 2015/2/1
UR - https://www.scopus.com/pages/publications/84922233505
U2 - 10.1378/chest.14-2296
DO - 10.1378/chest.14-2296
M3 - Article
C2 - 25522284
AN - SCOPUS:84922233505
SN - 0012-3692
VL - 147
SP - e73-e74
JO - CHEST
JF - CHEST
IS - 2
ER -